Published in

Oxford University Press, The Oncologist, 1(14), p. 104-105, 2009

DOI: 10.1634/theoncologist.2008-0222

Links

Tools

Export citation

Search in Google Scholar

Response to “Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting”

Journal article published in 2009 by Maggie Moore, Suzanne Kosmider, Kathryn Field, Jayesh Desai ORCID, Lionel Lim, Frances Barnett, Peter Gibbs
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background. The clinical trials on which the treatment ofadvancedcolorectal(CRC)isbasedenrollfewelderly patients. Furthermore, few investigations have deter- mined the use and outcomes of the treatment of ad- vanced CRC in practice. This study evaluated the treatment of advanced CRC in community oncology practices, focusing on age-related differences in treat- ment and outcome. Methods. A national, retrospective chart review was conducted to evaluate the management of advanced CRCin10communitypracticesacrosstheU.S.Allmed- ical records of patients diagnosed with advanced CRC initiating chemotherapy treatment after January 1, 2003 through 2006 were included. The primary aim was to compare the proportion receiving doublet chemo- therapy (irinotecan or oxaliplatin with a fluoropyrimi-